SSR-180,711

SSR-180,711
IUPAC ime
	(4-bromofenil) 1,4-diazabiciklo[3.2.2]nonan-4-karboksilat
Identifikatori
ATC kod	none
PubChem	CID 9928899
Hemijski podaci
Formula	C14H21BrN2O2
Molarna masa	329,232
	SMILES C2C[NH2](CC1)CCC[NH]12C(=O)Oc3ccc(Br)cc3; ;

SSR-180,711 je lek koji deluje kao potentan i selektivan parcijalni agonist za α7 tip neuronskog nikotinskog acetilholinskog receptora.^[1]^[2] U životinjskim studijama on je pokazao nutropne efekte, te potencijalno može da bude koristan u tretmanju šizofrenije.^[3]^[4]

Reference

^ Pichat, P.; Bergis, O.; Terranova, J.; Urani, A.; Duarte, C.; Santucci, V.; Gueudet, C.; Voltz, C.; Steinberg, R. (2007). „SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia”. Neuropsychopharmacology. 32 (1): 17—34. PMID 16936709. doi:10.1038/sj.npp.1301188.
^ Biton, B.; Bergis, O.; Galli, F.; Nedelec, A.; Lochead, A.; Jegham, S.; Godet, D.; Lanneau, C.; Santamaria, R. (2007). „SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile”. Neuropsychopharmacology. 32 (1): 1—16. PMID 17019409. doi:10.1038/sj.npp.1301189.
^ Hashimoto, K.; Ishima, T.; Fujita, Y.; Matsuo, M.; Kobashi, T.; Takahagi, M.; Tsukada, H.; Iyo, M. (2008). „Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711”. Biological Psychiatry. 63 (1): 92—97. PMID 17601496. doi:10.1016/j.biopsych.2007.04.034.
^ Barak, S.; Arad, M.; De Levie, A.; Black, M.; Griebel, G.; Weiner, I. (2009). „Pro-cognitive and antipsychotic efficacy of the alpha7 nicotinic partial agonist SSR180711 in pharmacological and neurodevelopmental latent inhibition models of schizophrenia”. Neuropsychopharmacology. 34 (7): 1753—1763. PMID 19158670. doi:10.1038/npp.2008.232.